FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

					Oi	occu	511 50(11) (JI LIIC	invesiment	Com	pariy Act	01 1340						
Name and Address of Reporting Person* AGUIAR ERIC				2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
AGUIF	AK EKIC				1				,	_				X Directo	or		10% Ov	vner
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year)						\dashv	Officer below)	(give title		Other (s below)	specify			
C/O BRI	DGEBIO P	HARMA, INC.			100/	1//2	021											
421 KIPI	LING STRI	EET			\vdash													
				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														,	iled by One	Repo	orting Perso	n
PALO A	LTO C	A	94301												iled by Mor		one Repo	
(City)	(S	tate)	(Zip)															
		Tab	le I - Non-	Deriva	ative	e Se	curities	s Ac	quired, D	isp	osed o	f, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date			Code (Instr. 5)				Benefici Owned F	es Form ally (D) o following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	,	Amount	(A) or (D)	Price		orted saction(s) tr. 3 and 4)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
		1	(e	։ց., pւ	uts,	cans						oie secu	irities)					
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				C	ode	v	(A)	(D)	Date Exercisable		kpiration ate	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$62.63	06/17/2021			A		38,895		(1)	06	6/16/2031	Common Stock	38,895	\$0.00	38,895	5	D	

Explanation of Responses:

1. The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

Remarks:

/s/ Brian Stephenson, Attorney-06/22/2021 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.